Molecular Medicine

, Volume 21, Issue 1, pp 657–664 | Cite as

Targeting Extracellular Cyclophilins Ameliorates Disease Progression in Experimental Biliary Atresia

  • Tatiana Iordanskaia
  • Miroslav Malesevic
  • Gunter Fischer
  • Tatiana Pushkarsky
  • Michael Bukrinsky
  • Evan P. Nadler
Research Article


Biliary atresia (BA) is a devastating liver disease of unknown etiology affecting children generally within the first 3 months of life. The disease is manifested by inflammation and subsequent obstruction of the extrahepatic bile ducts, fibrosis and liver failure. The mechanisms responsible for disease pathogenesis are not fully understood, but a number of factors controlled by the SMAD signaling pathway have been implicated. In this study, we investigated the role of a known proinflammatory factor, extracellular cyclophilin A (CypA), in the pathogenesis of biliary atresia using the rhesus rotavirus (RRV) murine model. We used a unique cyclosporine A derivative, MM284, which does not enter cells and therefore inactivates exclusively extracellular cyclophilins, as a potential treatment. We demonstrated that levels of CypA in plasma of RRV-infected mice were increased significantly, and that treatment of mice with MM284 prior to or one day after disease initiation by RRV infection significantly improved the status of mice with experimental BA: weight gain was restored, bilirubinuria was abrogated, liver infiltration by inflammatory cells was reduced and activation of the SMAD pathway and SMAD-controlled fibrosis mediators and tissue inhibitor of metalloproteinases (TIMP)-4 and matrix metalloproteinase (MMP)-7 was alleviated. Furthermore, treatment of human hepatic stellate cells with recombinant cyclophilin recapitulated SMAD2/3 activation, which was also suppressed by MM284 treatment. Our data provide the first evidence that extracellular cyclophilins activate the SMAD pathway and promote inflammation in experimental BA, and suggest that MM284 may be a promising therapeutic agent for treating BA and possibly other intrahepatic chronic disorders.



This work was funded in part by National Institutes of Health; Grant Number K08 DK083769.


  1. 1.
    Bezerra JA, et al. (2014) Use of corticosteroids after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START randomized clinical trial. JAMA. 311:1750–9.CrossRefGoogle Scholar
  2. 2.
    Riepenhoff-Talty M, et al. (1993) Group A rotaviruses produce extrahepatic biliary obstruction in orally inoculated newborn mice. Pediatr. Res. 33:394–9.PubMedGoogle Scholar
  3. 3.
    Czech-Schmidt G, Verhagen W, Szavay P, Leonhardt J, Petersen C. (2001) Immunological gap in the infectious animal model for biliary atresia. J. Surg. Res. 101:62–7.CrossRefGoogle Scholar
  4. 4.
    Nadler EP, et al. (2009) Integrin alphavbeta6 and mediators of extracellular matrix deposition are up-regulated in experimental biliary atresia. J. Surg. Res. 154:21–9.CrossRefGoogle Scholar
  5. 5.
    Yan L, Zucker S, Toole BP. (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb. Haemost. 93:199–204.PubMedGoogle Scholar
  6. 6.
    Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M. (2010) Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin. Exp. Immunol. 160:305–17.CrossRefGoogle Scholar
  7. 7.
    Yurchenko V, et al. (2001) CD147 is a signaling receptor for cyclophilin B. Biochem. Biophys. Res. Commun. 288:786–8.CrossRefGoogle Scholar
  8. 8.
    Yurchenko V, et al. (2002) Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J. Biol. Chem. 277:22959–65.CrossRefGoogle Scholar
  9. 9.
    Kim JY, Kim WJ, Kim H, Suk K, Lee WH. (2009) The stimulation of CD147 induces MMP-9 expression through ERK and NF-kappaB in macrophages: implication for atherosclerosis. Immune Netw. 9:90–7.CrossRefGoogle Scholar
  10. 10.
    Zhu P, et al. (2005) Expression of CD147 on monocytes/macrophages in rheumatoid arthritis: its potential role in monocyte accumulation and matrix metalloproteinase production. Arthritis Res. Ther. 7:R1023–33.CrossRefGoogle Scholar
  11. 11.
    Stemmy EJ, et al. (2011) Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation. Am. J. Respir. Cell Mol. Biol. 45:991–8.CrossRefGoogle Scholar
  12. 12.
    Balsley MA, et al. (2010) A cell-impermeable cyclosporine a derivative reduces pathology in a mouse model of allergic lung inflammation. J. Immunol. 185:7663–70.CrossRefGoogle Scholar
  13. 13.
    Gwinn WM, et al. (2006) Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J. Immunol. 177:4870–9.CrossRefGoogle Scholar
  14. 14.
    Arora K, et al. (2005) Extracellular cyclophilins contribute to the regulation of inflammatory responses. J. Immunol. 175:517–22.CrossRefGoogle Scholar
  15. 15.
    Kim JY, Kim H, Suk K, Lee WH. (2010) Activation of CD147 with cyclophilin a induces the expression of IFITM1 through ERK and PI3K in THP-1 cells. Mediators Inflamm. 2010:821940.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. (2008) Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology. 47:1299–310.CrossRefGoogle Scholar
  17. 17.
    Hamada H, et al. (2012) Inflammatory cytokine profiles during cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine. 60:681–5.CrossRefGoogle Scholar
  18. 18.
    Malesevic M, et al. (2010) A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. Angew Chem. Int. Ed. Engl. 49:213–5.CrossRefGoogle Scholar
  19. 19.
    Iordanskaia T, et al. (2013) Dysregulation of upstream and downstream transforming growth factor-beta transcripts in livers of children with biliary atresia and fibrogenic gene signatures. J. Pediatr. Surg. 48:2047–53.CrossRefGoogle Scholar
  20. 20.
    Malesevic M, et al. (2013) Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147. J. Med. Chem. 56:7302–11.CrossRefGoogle Scholar
  21. 21.
    Changho S, Ahmed AA. (2010) Neutrophils in biliary atresia. A study on their morphologic distribution and expression of CAP37. Pathol. Res. Pract. 206:314–7.CrossRefGoogle Scholar
  22. 22.
    Georgiev P, et al. (2008) Characterization of time-related changes after experimental bile duct ligation. Br. J. Surg. 95:646–56.CrossRefGoogle Scholar
  23. 23.
    Gujral JS, Farhood A, Bajt ML, Jaeschke H. (2003) Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology. 38:355–63.CrossRefGoogle Scholar
  24. 24.
    Kim H, et al. (2005) Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin. Immunol. 116:217–24.CrossRefGoogle Scholar
  25. 25.
    Yuan W, Ge H, He B. (2010) Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes. Atherosclerosis. 213:415–21.CrossRefGoogle Scholar
  26. 26.
    O’Reilly S, Ciechomska M, Cant R, van Laar JM. (2014) Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J. Biol. Chem. 289:9952–60.CrossRefGoogle Scholar
  27. 27.
    Fujii H, Kawada N. (2014) Fibrogenesis in alcoholic liver disease. World J. Gastroenterol. 20:8048–54.CrossRefGoogle Scholar
  28. 28.
    Das D, Barnes MA, Nagy LE. (2014) Anaphylatoxin C5a modulates hepatic stellate cell migration. Fibrogenesis Tissue Repair. 7:9.CrossRefGoogle Scholar
  29. 29.
    Schlegel J, et al. (2009) Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J. Mol. Biol. 391:518–35.CrossRefGoogle Scholar
  30. 30.
    Yurchenko V, Constant S, Bukrinsky M. (2006) Dealing with the family: CD147 interactions with cyclophilins. Immunology. 117:301–9.CrossRefGoogle Scholar
  31. 31.
    Bukrinsky M. (2014) Extracellular cyclophilins in health and disease. Biochim. Biophys. Acta. 2014, Nov 18 [Epub ahead of print].Google Scholar
  32. 32.
    Seko Y, et al. (2004) Hypoxia followed by reoxygenation induces secretion of cyclophilin A from cultured rat cardiac myocytes. Biochem. Biophys. Res. Commun. 317:162–8.CrossRefGoogle Scholar
  33. 33.
    Kim SH, Lessner SM, Sakurai Y, Galis ZS. (2004) Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am. J. Pathol. 164:1567–74.CrossRefGoogle Scholar
  34. 34.
    Sherry B, Yarlett N, Strupp A, Cerami A. (1992) Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc. Natl. Acad. Sci. U. S. A. 89:3511–5.CrossRefGoogle Scholar
  35. 35.
    Jin ZG, et al. (2000) Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ. Res. 87:789–96.CrossRefGoogle Scholar
  36. 36.
    Liao DF, et al. (2000) Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol. Chem. 275:189–96.CrossRefGoogle Scholar
  37. 37.
    Tian X, et al. (2010) Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection. J. Virol. 84:3373–81.CrossRefGoogle Scholar
  38. 38.
    Damsker JM, et al. (2009) Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology. 126:55–62.CrossRefGoogle Scholar
  39. 39.
    Wang CH, et al. (2014) CD147 up-regulates calcium-induced chemotaxis, adhesion ability and invasiveness of human neutrophils via a TRPM-7-mediated mechanism. Rheumatology. 53:2288–96.CrossRefGoogle Scholar
  40. 40.
    Seizer P, et al. (2011) Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler. Thromb. Vasc. Biol. 31:1377–86.CrossRefGoogle Scholar
  41. 41.
    Yoshida K, Murata M, Yamaguchi T, Matsuzaki K. (2014) TGF-beta/Smad signaling during hepatic fibro-carcinogenesis (review). Int. J. Oncol. 45:1363–71.CrossRefGoogle Scholar
  42. 42.
    Hoffmann H, Schiene-Fischer C. (2014) Functional aspects of extracellular cyclophilins. Biol. Chem. 395:721–35.PubMedGoogle Scholar
  43. 43.
    Hayashida T, Decaestecker M, Schnaper HW. (2003) Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J. 17:1576–8.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Tatiana Iordanskaia
    • 1
  • Miroslav Malesevic
    • 2
  • Gunter Fischer
    • 3
  • Tatiana Pushkarsky
    • 4
  • Michael Bukrinsky
    • 4
  • Evan P. Nadler
    • 1
  1. 1.Division of Pediatric SurgeryChildren’s National Medical CenterWashingtonUSA
  2. 2.Institute of BiochemistryMartin Luther-University Halle-WittenbergHalleGermany
  3. 3.Max-Planck-Institute for Biophysical Chemistry GottingenHalleGermany
  4. 4.George Washington University School of Medicine and Health Sciences, Department of MicrobiologyImmunology and Tropical Medicine Washington, District of ColumbiaWashingtonUSA

Personalised recommendations